Brief: Wuhan YZY Biopharma Sees Decrease In Consolidated Loss By No Less Than 35% For Year
24/03/2025 16:47
March 24 (Reuters) - Wuhan YZY Biopharma Co Ltd 2496.HK: EXPECTED DECREASE IN CONSOLIDATED LOSS BY NO LESS THAN 35% FOR YEAR REDUCTION IN LOSS ATTRIBUTED TO LICENSE AGREEMENT AND LOWER EXPENSES IN FY Further company coverage: 2496.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wuhan YZY Biopharma
See all newsBrief: HKEX Says Trading In Wuhan Yzy Biopharma H Shares Halted
Brief: Wuhan Yzy Biopharma Co Says NDA For M701 Accepted By NMPA For Treatment Of Malignant Ascites
Brief: Wuhan Yzy Biopharma Says M701 Receives IND Approval From FDA
Brief: Wuhan YZY Biopharma Says Wuhan Yiruide To Buy Land Use Right And Building
Brief: Wuhan Yzy Biopharma Says Y225 Receives IND Approval From NMPA